Vaccines

Five things for pharma marketers to know: Wednesday, November 30, 2016

Five things for pharma marketers to know: Wednesday, November 30, 2016

By

Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey

Pfizer expands humanitarian access to Prevnar 13 vaccine

Pfizer expands humanitarian access to Prevnar 13 vaccine

By

Pfizer expanded its humanitarian efforts by providing the Prevnar 13 vaccine at a low price and donating proceeds to aid groups.

Five things for pharma marketers to know: Monday, October 24, 2016

Five things for pharma marketers to know: Monday, October 24, 2016

By

GSK files for FDA approval of shingles vaccine; Chinese drugmaker reportedly files for largest IPO since 2013; Sunovion completes deal to buy Cynapsus

Five things for pharma marketers to know: Wednesday, October 19, 2016

Five things for pharma marketers to know: Wednesday, October 19, 2016

By

Roche gets FDA approval for immunotherapy Tecentriq; insurers are sued for discrimination; the FDA proposes yanking generic ADHD drugs from market

Five things for pharma marketers to know: Monday, October 17, 2016

Five things for pharma marketers to know: Monday, October 17, 2016

By

Doctors Without Borders refuses free Pfizer vaccines; Valeant to raise prices of certain drugs; two urologists advocate for overactive bladder drugs

Five things for pharma marketers to know: Thursday, September 15, 2016

Five things for pharma marketers to know: Thursday, September 15, 2016

By

Mylan CEO to appear before House committee about EpiPen pricing; job-related health premiums rise; GSK's experimental shingles vaccine shows 90% effectiveness

Five things for pharma marketers to know: Wednesday, August 31, 2016

Five things for pharma marketers to know: Wednesday, August 31, 2016

By

The FDA approves an Enbrel biosimilar; Express Scripts to launch program to reduce diabetes costs; a GSK vaccine beats sales forecasts

Five things for pharma marketers to know: Thursday, August 4, 2016

Five things for pharma marketers to know: Thursday, August 4, 2016

By By

Researchers test Zika vaccine; Aetna contacts doctors who prescribe high rates of opioids; half of pediatric trials are never published or completed

Five things for pharma marketers to know: Thursday, July 21, 2016

Five things for pharma marketers to know: Thursday, July 21, 2016

By

The FDA approves generic versions of AstraZeneca's Crestor; Biogen CEO steps down; drugmakers race to develop smart inhalers

Five things for pharma marketers to know: Thursday, July 14, 2016

Five things for pharma marketers to know: Thursday, July 14, 2016

By

The FDA expands use for Pfizer's Prevnar 13 vaccine; an FDA panel votes in support of Novartis biosimilar; U.S. healthcare spending rises 5.5% in 2015

Five things for pharma marketers to know: Monday, February 22, 2016

Five things for pharma marketers to know: Monday, February 22, 2016

Merck CEO says industry needs to better communicate value; procedural vote could clear Califf as FDA chief; HPV vaccine lowers virus' prevalence

Five things for pharma marketers to know: Friday, February 19, 2016

Five things for pharma marketers to know: Friday, February 19, 2016

By

Cancer MoonShot 2020 to study childhood cancers; IBM's purchase of Truven provides data about 200 million patients; overdoses tied to benzodiazepines rise

Paul Newman to lead Takeda's vaccines comms

Paul Newman to lead Takeda's vaccines comms

By

The former MSL regional leader reemerges as head of communications at Japan's largest pharma company.

Pfizer delivers strong Prevnar sales on back of big '15 consumer media outlay

Pfizer delivers strong Prevnar sales on back of big '15 consumer media outlay

By

Company's vaccines chief credits campaigns aimed at grownups with driving US demand for blockbuster vaccine. The remaining cohort will be harder to capture.

Five things for pharma marketers to know: Tuesday, September 15, 2015

Five things for pharma marketers to know: Tuesday, September 15, 2015

By

GSK awards its global media buying business; one-third of patients dropped out of Xenoport psoriasis trial; an experimental drug for liver disease fails to meet primary endpoints

Is It Time to Change the Vaccine Dialogue? Campaigns Present Opportunities for Pharma

Is It Time to Change the Vaccine Dialogue? Campaigns Present Opportunities for Pharma

While social media can be a tool for pharma to help educate the public, it has also become a forum for the public to express their views about pharma, and it's not always flattering, as evidenced by the recent antivaccine movement.

Five things for pharma marketers to know: Thursday, July 2

Five things for pharma marketers to know: Thursday, July 2

By

Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs

Pfizer reports uptake for cancer-therapy Ibrance

Pfizer reports uptake for cancer-therapy Ibrance

By

Sales of the new cancer drug topped expectations since its February launch.

Five things for pharma marketers to know: Wednesday, April 22

Five things for pharma marketers to know: Wednesday, April 22

By

Study finds vaccines still not linked to autism; investments in healthcare start-ups hit record high this year; biosimilars are already bearing down on prices overseas

Five things for pharma marketers to know: Thursday, April 2

Five things for pharma marketers to know: Thursday, April 2

By

Celltrion expects its Remicade biosimilar to hit the US this year; Vivus cuts its sales force; BMJ accuses Novartis of interfering with clinical trials

Five things for pharma marketers to know: Tuesday, February 24

Five things for pharma marketers to know: Tuesday, February 24

By

FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.

Five things for pharma marketers to know: Monday, February 9

Five things for pharma marketers to know: Monday, February 9

By

Achillion's experimental HCV drug cleared the virus in six weeks when combined with Gilead's Sovaldi; Sanofi will replace a third of its sales managers; GSK shutters Montana vaccine R&D.

Education effort provides measles/pertussis cheat sheet

Education effort provides measles/pertussis cheat sheet

By

Measles outbreak news aside, doctors need help identifying illnesses vaccines have made uncommon.

Five things for pharma marketers to know: Monday, February 2

Five things for pharma marketers to know: Monday, February 2

By By

Pfizer ends spinal muscular atrophy collaboration; abuse-deterrent Zohydro scores approval; measles outbreak at Disneyland linked to 36 cases.

Approval pits Novartis meningococcal vaccine against Pfizer shot

FDA has approved Novartis's Bexsero after approving Pfizer's Trumemba this past October.

Five things for pharma marketers to know: Tuesday, January 20

Five things for pharma marketers to know: Tuesday, January 20

By

FDA draws fine line between health and wellness apps; Colorado gives biosimilar swap law another look; ZMapp is set to start human trials of its Ebola vaccine.

J&J inks Alzheimer's vaccine deal

The $509-million agreement gives J&J rights to AC Immune's experimental anti-Tau vaccine.

Gates Foundation sponsors campaign to promote vaccinations

The artwork is meant to inspire debate and donations for vaccinations.

Five things for pharma marketers to know: Tuesday, January 6

Five things for pharma marketers to know: Tuesday, January 6

By

Pfizer continues to scoop up vaccine assets, Dendreon heads to auction with no lead bidder, Genentech and 23andMe will take on the Parkinson's genome.

GSK shingles vax shaping up to compete with Merck's

GSK shingles vax shaping up to compete with Merck's

By

The Herpes zoster vaccine candidate showed relatively strong efficacy in a Phase-III trial, but its dosing is less convenient than an older product sold by rival Merck.

OPINION

Email Newsletters